Lenalidomid Teva (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex. This binding changes the complex’s substrate specificity, leading to the ubiquitination and degradation of transcription factors Ikaros and Aiolos. The resulting actions include anti‑angiogenic effects, modulation of the immune response, and direct inhibition of malignant cell proliferation.

The specific dose of Lenalidomid Teva is determined by the prescribing clinician based on the patient’s diagnosis, disease stage, renal function, and other individual factors. Healthcare professionals follow approved labeling and clinical guidelines to select the appropriate dosage and schedule for each patient.

Lenalidomid Teva is classified as teratogenic and is contraindicated in pregnancy. Women of childbearing potential must use effective contraception before, during, and after treatment. Safety during breastfeeding has not been established, and breastfeeding is generally not recommended while taking lenalidomide.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Lenalidomid Teva belongs to the immunomodulatory imide drug class, offering a distinct mechanism compared with proteasome inhibitors or monoclonal antibodies used in similar indications. Its oral administration and ability to target cereblon‑mediated pathways provide an alternative or complementary option, often selected based on patient tolerance, prior therapy, and specific disease characteristics.

Lenalidomid Teva should be stored at room temperature, below 25 °C, in its original packaging. The container protects the product from moisture and light, helping maintain stability throughout its shelf life.

Lenalidomid Teva is taken orally, usually with or without food, as directed by the prescribing physician. The tablets are swallowed whole with a glass of water and the dosing schedule is individualized for each patient.

The most serious risks include severe neutropenia or thrombocytopenia, which can lead to infections or bleeding, venous thromboembolism, secondary primary malignancies, and rare but life‑threatening reactions such as tumor lysis syndrome or severe hypersensitivity. Patients should be monitored closely for these events.

Lenalidomid Teva is contraindicated in patients with known hypersensitivity to lenalidomide or any component of the formulation, in pregnant women, and in individuals who cannot adhere to strict contraceptive measures. Caution is also advised for patients with severe renal impairment or uncontrolled infections.